Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHAMMED M MILHEM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1558429100
CMS profile
806076
Location
IOWA CITY, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$53.18

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $53.18 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $53.18 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHAMMED M MILHEM

NPI 1558429100 · CMS profile ID 806076

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

IOWA CITY, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $53.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $53.1804/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242511626 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,538.13 7
PY2021 $18.12 2
PY2022 $21.70 2
PY2025 $53.18 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,472.81 4
PY2025 Principal investigator $581,246.58 77
PY2024 Principal investigator $999,952.01 109
PY2023 Recipient $1,270.00 2
PY2023 Principal investigator $827,610.63 137
PY2022 Principal investigator $1,233,503.31 110
PY2021 Principal investigator $751,345.38 31
PY2020 Principal investigator $896,218.13 99
PY2019 Recipient $476.00 1
PY2019 Principal investigator $1,105,673.41 103

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

104 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $5,975.00 12/31/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691466053
Principal investigator 1 Amgen Inc. $2,550.00 12/20/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
P1b2 talimogene laherparepvec + Yervoy combo melanoma No dispute reported 06/30/2026 675781025
Principal investigator 1 Merck Sharp & Dohme Corporation $1,880.60 12/19/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691464897
Principal investigator 1 Genentech, Inc. $33,451.00 12/13/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
FAP IL2V FP CHECKPOINT INHIBITOR COMBINATION STUDY No dispute reported 06/30/2026 681096089
Principal investigator 1 Merck Sharp & Dohme Corporation $10,826.24 12/09/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691538165
Principal investigator 1 PFIZER INC. $15,264.90 12/02/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671680951
Principal investigator 1 Merck Sharp & Dohme Corporation $512.00 11/25/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 691533607
Principal investigator 1 Merck Sharp & Dohme Corporation $10,826.24 11/21/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 691538163
Principal investigator 1 Merck Sharp & Dohme Corporation $3,761.20 11/19/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691503495
Principal investigator 1 Merck Sharp & Dohme Corporation $93.60 11/05/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 691535055
Principal investigator 1 PFIZER INC. $800.00 10/29/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671681019
Principal investigator 1 Merck Sharp & Dohme Corporation $905.78 10/28/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 691533615
Principal investigator 1 Merck Sharp & Dohme Corporation $10,826.24 10/28/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691538161
Principal investigator 1 PFIZER INC. $825.30 10/22/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671681015
Principal investigator 1 PFIZER INC. $350.00 10/22/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671681017
Principal investigator 1 TESARO, Inc. $15,012.00 10/22/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408869
Principal investigator 1 TESARO, Inc. $7,400.00 10/22/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408871
Principal investigator 1 Merck Sharp & Dohme Corporation $1,880.60 10/17/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691422347
Principal investigator 1 Merck Sharp & Dohme Corporation $10,826.24 10/14/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 691535893
Principal investigator 1 Merck Sharp & Dohme Corporation $523.20 10/10/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 691533611
Principal investigator 1 Amgen Inc. $390.66 10/08/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
P1b2 talimogene laherparepvec + Yervoy combo melanoma No dispute reported 06/30/2026 675781027
Principal investigator 1 Dynavax Technologies Corporation $1,650.00 10/08/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 696040819
Principal investigator 1 Dynavax Technologies Corporation $300.00 10/08/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 696040821
Principal investigator 1 Dynavax Technologies Corporation $450.00 10/08/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 696040823
Principal investigator 1 PFIZER INC. $2,450.00 10/01/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671680953
Principal investigator 1 TESARO, Inc. $4,179.00 09/26/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408863
Principal investigator 1 TESARO, Inc. $753.00 09/26/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408865
Principal investigator 1 Merck Sharp & Dohme Corporation $3,000.00 09/25/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma No dispute reported 06/30/2026 691458405
Principal investigator 1 Merck Sharp & Dohme Corporation $35,620.00 09/25/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma No dispute reported 06/30/2026 691458479
Principal investigator 1 Dynavax Technologies Corporation $2,860.00 09/24/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 696040729
Principal investigator 1 Dynavax Technologies Corporation $650.00 09/24/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 696040745
Principal investigator 1 Dynavax Technologies Corporation $1,430.00 09/24/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 696040749
Principal investigator 1 PFIZER INC. $1,209.60 09/24/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671680813
Principal investigator 1 PFIZER INC. $151.20 09/24/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671680815
Principal investigator 1 PFIZER INC. $403.20 09/24/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671680817
Principal investigator 1 PFIZER INC. $403.20 09/24/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671680851
Principal investigator 1 PFIZER INC. $107.10 09/24/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671680853
Principal investigator 1 PFIZER INC. $107.10 09/24/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671680855
Principal investigator 1 PFIZER INC. $151.20 09/24/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671680895
Principal investigator 1 PFIZER INC. $151.20 09/24/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671680897
Principal investigator 1 PFIZER INC. $459.90 09/24/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671680949
Principal investigator 1 Merck Sharp & Dohme Corporation $301.10 09/18/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 691537777
Principal investigator 1 Merck Sharp & Dohme Corporation $2,150.00 09/16/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 691367053
Principal investigator 1 Merck Sharp & Dohme Corporation $10,826.24 09/16/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691454681
Principal investigator 1 Amgen Inc. $4,520.00 09/12/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Retreatment Trial - Ph2 Re-treatment after relapse after blinatumomab treatment (US/EU) No dispute reported 06/30/2026 675781047
Principal investigator 1 Merck Sharp & Dohme Corporation $3,761.20 09/10/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691368239
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 09/10/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 691454967
Principal investigator 1 PFIZER INC. $650.00 08/27/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671680775
Principal investigator 1 PFIZER INC. $4,500.00 08/27/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671680777
Principal investigator 1 PFIZER INC. $2,850.00 08/27/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671680899
Principal investigator 1 Merck Sharp & Dohme Corporation $983.07 08/20/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 691535053
Principal investigator 1 Merck Sharp & Dohme Corporation $10,826.24 08/16/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 691456521
Principal investigator 1 Merck Sharp & Dohme Corporation $1,880.60 08/15/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691368161
Principal investigator 1 Merck Sharp & Dohme Corporation $10,826.24 08/05/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691454679
Principal investigator 1 Dynavax Technologies Corporation $8,038.80 07/30/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 696040741
Principal investigator 1 Merck Sharp & Dohme Corporation $3,761.20 07/23/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691368235
Principal investigator 1 Amgen Inc. $6,790.00 07/20/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
P1b2 talimogene laherparepvec + Yervoy combo melanoma No dispute reported 06/30/2026 675781023
Principal investigator 1 Merck Sharp & Dohme Corporation $7,124.00 07/19/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma No dispute reported 06/30/2026 709106497
Principal investigator 1 Merck Sharp & Dohme Corporation $33,839.00 07/19/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma No dispute reported 06/30/2026 709106499
Principal investigator 1 Merck Sharp & Dohme Corporation $10,826.24 07/17/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 691456517
Principal investigator 1 Merck Sharp & Dohme Corporation $3,652.50 07/05/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 691365173
Principal investigator 1 Merck Sharp & Dohme Corporation $580.14 07/05/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 691486803
Principal investigator 1 Merck Sharp & Dohme Corporation $2,208.60 07/05/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 691488951
Principal investigator 1 Merck Sharp & Dohme Corporation $1,800.00 07/03/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma No dispute reported 06/30/2026 691459571
Principal investigator 1 TESARO, Inc. $4,211.00 07/02/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408853
Principal investigator 1 TESARO, Inc. $1,292.00 07/02/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408855
Principal investigator 1 TESARO, Inc. $2,645.00 07/02/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408857
Principal investigator 1 Merck Sharp & Dohme Corporation $230.40 06/24/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 691342261
Principal investigator 1 Merck Sharp & Dohme Corporation $10,826.24 06/24/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691456513
Principal investigator 1 Merck Sharp & Dohme Corporation $1,880.60 06/13/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691368157
Principal investigator 1 Amgen Inc. $542.85 06/05/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
P3 OPTiM Melanoma No dispute reported 06/30/2026 675781031
Principal investigator 1 PFIZER INC. $1,170.00 06/04/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671636739
Principal investigator 1 Dynavax Technologies Corporation $47,569.59 05/21/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 696040719
Principal investigator 1 Dynavax Technologies Corporation $26,934.26 05/20/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 696041141
Principal investigator 1 Merck Sharp & Dohme Corporation $1,261.20 05/14/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691368230
Principal investigator 1 Merck Sharp & Dohme Corporation $10,826.24 05/13/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691456440
Principal investigator 1 PFIZER INC. $27,168.31 05/07/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671636741
Principal investigator 1 Merck Sharp & Dohme Corporation $14,700.00 05/02/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691368155
Principal investigator 1 Merck Sharp & Dohme Corporation $62.40 04/27/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 691490829
Principal investigator 1 Merck Sharp & Dohme Corporation $10,904.96 04/16/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 691454395
Principal investigator 1 Merck Sharp & Dohme Corporation $1,880.60 04/09/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691323125
Principal investigator 1 PFIZER INC. $927.68 04/02/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671636737
Principal investigator 1 PFIZER INC. $927.68 04/02/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671636753
Principal investigator 1 PFIZER INC. $14,198.65 04/02/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671636755
Principal investigator 1 Merck Sharp & Dohme Corporation $10,826.24 04/01/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691456437
Principal investigator 1 PFIZER INC. $333.28 03/21/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671621149
Principal investigator 1 Celgene Corporation $24,366.06 03/19/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects (CC-486-CAGEN-001) No dispute reported 06/30/2026 675417477
Principal investigator 1 Merck Sharp & Dohme Corporation $5,176.20 03/19/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691323509
Principal investigator 1 TESARO, Inc. $2,953.00 03/19/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408837
Principal investigator 1 TESARO, Inc. $4,768.00 03/19/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408839
Principal investigator 1 Merck Sharp & Dohme Corporation $8.44 03/15/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 691344145
Principal investigator 1 PFIZER INC. $130,972.15 03/07/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671621153
Principal investigator 1 Merck Sharp & Dohme Corporation $31.20 03/05/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 691490467
Recipient Celgene Corporation $476.00 03/01/2019 Covered Recipient Physician A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects (CC-486-CAGEN-001) No dispute reported 06/30/2026 675414319
Principal investigator 1 Amgen Inc. $96,841.00 02/26/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec with Concurrent Preoperative Radiation in Patients with Locally Advanced Soft Tissue Sarcomas No dispute reported 06/30/2026 675781021
Principal investigator 1 Merck Sharp & Dohme Corporation $10,830.76 02/18/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691295997
Principal investigator 1 Dynavax Technologies Corporation $56,607.39 01/29/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 696040651
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,126.00 01/29/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
MODULAR PHASE 2 STUDY TO LINK COMBINATION IMMUNE THERAPY TO PATIENTS WITH ADVANCED SOLID AND HEMATOLOGIC MALIGNANCIES MODULE 1 PDR001 PLUS LAG525 FOR PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 640708921
Principal investigator 1 Merck Sharp & Dohme Corporation $21,661.52 01/23/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial No dispute reported 06/30/2026 691295895
Principal investigator 1 TESARO, Inc. $10,520.00 01/15/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408829
Principal investigator 1 TESARO, Inc. $12,097.00 01/15/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 689408831
Principal investigator 1 PFIZER INC. $11,900.00 01/03/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671621089
Principal investigator 1 PFIZER INC. $149,834.48 01/03/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671621091
Principal investigator 1 PFIZER INC. $8,360.00 01/03/2019 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB0010718C IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671621151